Daniel Lebovic

3.4k total citations
41 papers, 1.0k citations indexed

About

Daniel Lebovic is a scholar working on Hematology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Lebovic has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 23 papers in Molecular Biology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Lebovic's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Daniel Lebovic is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Daniel Lebovic collaborates with scholars based in United States, Poland and Singapore. Daniel Lebovic's co-authors include Andrzej Jakubowiak, Mark Kaminski, Kent A. Griffith, Keith Stockerl‐Goldstein, Ravi Vij, Sundar Jagannath, Dominik Dytfeld, Tara Anderson, Kristen Detweiler‐Short and Kathryn McDonnell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Daniel Lebovic

38 papers receiving 983 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Lebovic United States 14 712 557 427 199 135 41 1.0k
Katarina Luptakova United States 14 521 0.7× 460 0.8× 698 1.6× 87 0.4× 96 0.7× 50 1.1k
P. Leif Bergsagel United States 9 1.2k 1.7× 1.4k 2.5× 694 1.6× 116 0.6× 206 1.5× 10 1.6k
Sarah Brennan United States 8 492 0.7× 308 0.6× 379 0.9× 143 0.7× 78 0.6× 12 801
Tiffany Khong Australia 17 678 1.0× 466 0.8× 275 0.6× 87 0.4× 97 0.7× 52 908
Sophie Derenne France 8 418 0.6× 338 0.6× 362 0.8× 88 0.4× 59 0.4× 11 780
Maurizio Affer United States 11 571 0.8× 401 0.7× 176 0.4× 83 0.4× 92 0.7× 22 843
Simon He Australia 9 470 0.7× 259 0.5× 245 0.6× 151 0.8× 251 1.9× 14 846
Wijith Munasinghe United States 17 438 0.6× 334 0.6× 464 1.1× 140 0.7× 357 2.6× 47 950
C. Vasselon France 11 625 0.9× 420 0.8× 273 0.6× 102 0.5× 139 1.0× 27 964

Countries citing papers authored by Daniel Lebovic

Since Specialization
Citations

This map shows the geographic impact of Daniel Lebovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lebovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lebovic more than expected).

Fields of papers citing papers by Daniel Lebovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Lebovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lebovic. The network helps show where Daniel Lebovic may publish in the future.

Co-authorship network of co-authors of Daniel Lebovic

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Lebovic. A scholar is included among the top collaborators of Daniel Lebovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Lebovic. Daniel Lebovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richardson, Paul G., William Bensinger, Carol Ann Huff, et al.. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology. 180(6). 821–830. 30 indexed citations
2.
Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations
3.
Khan, Uqba, et al.. (2016). Sweet syndrome: a painful reality. BMJ Case Reports. 2016. bcr2016217606–bcr2016217606. 6 indexed citations
4.
Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations
5.
Touzeau, Cyrille, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2015). Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 33(15_suppl). 8580–8580. 3 indexed citations
6.
Elstrom, Rebecca, Jia Ruan, Paul J. Christos, et al.. (2014). Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab. Leukemia & lymphoma. 56(2). 342–346. 10 indexed citations
7.
Raab, Marc S., Enrique M. Ocio, Sheeba K. Thomas, et al.. (2014). Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma. Blood. 124(21). 301–301. 26 indexed citations
8.
9.
Vij, Ravi, Carol Ann Huff, William Bensinger, et al.. (2014). Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. Blood. 124(21). 31–31. 9 indexed citations
10.
Jasielec, Jagoda, Dominik Dytfeld, Kent A. Griffith, et al.. (2013). Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). Blood. 122(21). 3220–3220. 3 indexed citations
11.
Malek, Sami N., Mark Kaminski, Hongxiu Li, et al.. (2013). Recurrent STAT6 Mutations In Follicular Lymphoma. Blood. 122(21). 503–503.
12.
Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 120(9). 1801–1809. 311 indexed citations
13.
Lebovic, Daniel, Mark Kaminski, Tara Anderson, et al.. (2012). A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM). Blood. 120(21). 1854–1854. 7 indexed citations
14.
15.
Advani, Ranjana H., Daniel Lebovic, Mark W. Brunvand, et al.. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 120(21). 59–59. 11 indexed citations
16.
17.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations
18.
Baz, Rachid, Mehul Patel, Daniel Lebovic, et al.. (2010). Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leukemia & lymphoma. 51(6). 1015–1019. 13 indexed citations
19.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2010). Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. Blood. 116(21). 862–862. 12 indexed citations
20.
Lebovic, Daniel, Alberto Chiappori, & Jhanelle E. Gray. (2010). Maintenance therapies in advanced non-small-cell lung cancer. Therapy. 8(1). 33–41.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katarina Luptakova Breakdown of academic impact, for papers by P. Leif Bergsagel Breakdown of academic impact, for papers by Sarah Brennan Breakdown of academic impact, for papers by Tiffany Khong Breakdown of academic impact, for papers by Sophie Derenne Breakdown of academic impact, for papers by Maurizio Affer Breakdown of academic impact, for papers by Simon He Breakdown of academic impact, for papers by Wijith Munasinghe Breakdown of academic impact, for papers by C. Vasselon
Rankless by CCL
2026